RxDoctor Payments DataLook up a doctor →

Lindsey Finklea, MD

Dermatology · San Antonio, TXNPI 1528294055

Payments from drug & device makers

$1,166,261in general payments, 2019–2025

Across 2,037 payments — averaging $572.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$509K
  • Lilly USA, LLC$154K
  • Incyte Corporation$133K
  • Regeneron$129K
  • AbbVie$84K
  • Regeneron Healthcare Solutions, Inc.$41K
  • plus $117K from 47 others
$3,956in research payments, 2019–2025

Across 5 payments — averaging $791.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2K
  • Regeneron$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,166,261 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$403,340
Medicare patients
535
Services billed
4,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →